Issie Kirby
Stock Analyst at Rothschild & Co Redburn
(1.27)
# 3,802
Out of 5,133 analysts
19
Total ratings
25%
Success rate
-2.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Issie Kirby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MMED MiniMed Group | Initiated Coverage: Buy | $30 | $17.99 | +66.76% | 1 | Oct 13, 2026 | |
| PODD Insulet | Downgraded: Hold | $235 → $220 | $152.48 | +44.28% | 2 | Apr 24, 2026 | |
| TNDM Tandem Diabetes Care | Reiterated: Buy | $60 → $45 | $20.07 | +124.22% | 2 | Apr 24, 2026 | |
| SWX: ALC Alcon Inc. | Reiterated: Buy | CHF 93.00 → CHF 77.00 | CHF 61.36 | +25.49% | 4 | Mar 4, 2026 | |
| COO The Cooper Companies | Downgraded: Hold | $125 → $85 | $62.65 | +35.67% | 3 | Mar 4, 2026 | |
| SWX: SOON Sonova Holding AG | Upgraded: Hold | CHF 225.00 → CHF 215.00 | CHF 286.20 | n/a | 4 | Oct 6, 2025 | |
| EPA: EL EssilorLuxottica Société anonyme | Upgraded: Buy | €320.00 | €182.35 | n/a | 1 | Sep 17, 2025 | |
| DXCM DexCom | Upgraded: Buy | $130 → $115 | $83.33 | n/a | 2 | Feb 3, 2025 |
MiniMed Group
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $17.99
Upside: +66.76%
Insulet
Apr 24, 2026
Downgraded: Hold
Price Target: $235 → $220
Current: $152.48
Upside: +44.28%
Tandem Diabetes Care
Apr 24, 2026
Reiterated: Buy
Price Target: $60 → $45
Current: $20.07
Upside: +124.22%
Alcon Inc.
Mar 4, 2026
Reiterated: Buy
Price Target: CHF 93.00 → CHF 77.00
Current: CHF 61.36
Upside: +25.49%
The Cooper Companies
Mar 4, 2026
Downgraded: Hold
Price Target: $125 → $85
Current: $62.65
Upside: +35.67%
Sonova Holding AG
Oct 6, 2025
Upgraded: Hold
Price Target: CHF 225.00 → CHF 215.00
Current: CHF 286.20
Upside: n/a
EssilorLuxottica Société anonyme
Sep 17, 2025
Upgraded: Buy
Price Target: €320.00
Current: €182.35
Upside: n/a
DexCom
Feb 3, 2025
Upgraded: Buy
Price Target: $130 → $115
Current: $83.33
Upside: n/a